Resensitizing Triple-Negative Breast Cancer: Targeting the YES1 Protein

episode

Cleveland Clinic Cancer Advances not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

A.I. Safety Goes Mainstream + a ‘Hard Fork’ Exit AMA 1h 25m · 18 Sep 2026 · Hard Fork

Layoffs at the Kansas City Star will hurt local communities 15 min · 18 Sep 2026 · Kansas City Today

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026 · EyeCode Media

Planning Commission Meeting - Sep 17, 2026 1h 11m · 17 Sep 2026 · Leesburg Planning Commission

Heritage Commission - Sep 14, 2026 1h 57m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Historic District Review Committee - Sep 14, 2026 1h 36m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Report any issue

Source

Recorded23 Jan 2025

Publisherfeeds.buzzsprout.com

Handlerec:1648155

Show notes

Ruth Keri, PhD, Associate Director for Basic Research at Case Comprehensive Cancer Center and Professor of Cancer Biology at Cleveland Clinic, returns to the Cancer Advances Podcast to share the latest advancements in targeting YES1 protein to treat triple-negative breast cancer (TNBC). Listen as Dr. Keri discusses how YES1 impacts chemotherapy resistance, tumor growth, and EGFR inhibition, uncovering promising therapeutic opportunities and the potential clinical trials to improve outcomes for patients facing this aggressive cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in